Eloralintide for knee osteoarthritis pain in adults who are overweight or have obesity
Tests eloralintide against placebo in adults with painful knee osteoarthritis and excess weight.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Key facts
- Where
- Chiba, Chūōku, Kitakyushu-Shi, Miyazaki, Nagareyama, Ōita, Saitama, Sashima, Sendai, Shinagawa-ku Tokyo, Suginami City, Toyohashi, and Yamagata, JapanSee the 15 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with knee osteoarthritis pain who also have overweight or obesity (BMI of 27 kg/m² or higher) and have not lost weight through diet.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Osteoarthritis of the knee with pain, and at least one of: over 50 years old, morning knee stiffness lasting about 30 minutes, or a crackling or grinding feeling in the knee.
- Earlier treatment
- Must have tried at least once to lose weight through diet without success. Must not have taken weight-loss medications or alternative remedies within 90 days of screening.
- Biomarker or test result
- BMI of 27 kg/m² or higher at screening; stable body weight (less than 5% change) for 90 days before screening.
Main reasons for not taking part
- Any type of diabetes (type 1, type 2 or other)
- Surgery or endoscopic or device-based treatment for obesity (some exceptions if long ago)
- Active knee infection
- Heart attack, stroke, coronary artery revascularization, unstable angina or hospitalization for heart failure within 90 days before screening
- Class IV congestive heart failure (New York Heart Association)
Read by machine on 9 November 2026.
Where in Japan
- National Hospital Organization Chiba Medical CenterChiba, JapanTaking people
- Tokyo Asbo ClinicChūōku, JapanTaking people
- Tokyo-Eki Center-building ClinicChūōku, JapanTaking people
- Shin Komonji HospitalKitakyushu-Shi, JapanTaking people
- Goto Orthopedic Surgery ClinicMiyazaki, JapanTaking people
- Komagidai ClinicNagareyama, JapanTaking people
- Fujigaki ClinicŌita, JapanTaking people
- Saitama City HospitalSaitama, JapanTaking people
- Ibaraki Seinan Medical Center HospitalSashima, JapanTaking people
- Katsura Garden OrthopedicsSendai, JapanTaking people
- Ogura Orthopedics SurgerySendai, JapanTaking people
- Ooimachi Orthopedic Surgery and surgery ClinicShinagawa-ku Tokyo, JapanTaking people
- Masumoto Orthopedics ClinicSuginami City, JapanTaking people
- National Hospital Organization Toyohashi Medical CenterToyohashi, JapanTaking people
- Yamagata Tokushukai HospitalYamagata, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07353931EU 2025-523768-19-00
- Record updated
- 4 November 2026
- Original description
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.Read full original descriptionShow less
A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.
Inclusion: Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening; Have a stable body weight (less than 5% body weight change) for 90 days prior to screening; Have tried at least once to lose weight through diet but were unsuccessful; Have osteoarthritis of the knee and at least one of the following conditions:; Be over 50 years old; Have morning knee stiffness that lasts about 30 minutes; Have a crackling or grinding sound or feeling in the knee.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed greater than 1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes, type 2 diabetes, or any other type of diabetes; Have an active knee infection; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure.